Cytosorbents (CTSO) EBITDA (2010 - 2026)

Cytosorbents (CTSO) has reported EBITDA for 17 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 27.03% year-over-year to -$2.6 million; the trailing twelve-month figure through Jun 2026 stood at -$12.9 million (up 17.8% YoY), and the FY2025 full-year result was -$14.7 million, up 10.35% from the prior year.
• EBITDA grew to -$2.6 million in Q2 2026 per CTSO's latest filing, from -$3.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.6 million in Q2 2026 and bottomed at -$9.4 million in Q4 2023.
• Historically, EBITDA has averaged -$5.5 million across 5 years, with a median of -$4.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBITDA slumped 173.16% in 2022, then surged 63.91% in 2024.
• Over 5 years, EBITDA stood at -$6.4 million in 2022, then sank by 48.01% to -$9.4 million in 2023, then soared by 63.91% to -$3.4 million in 2024, then decreased by 29.16% to -$4.4 million in 2025, then soared by 39.84% to -$2.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.6 million, -$3.0 million, and -$4.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.